Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
Rhea-AI Summary
Onconetix (Nasdaq: ONCO) highlighted that Realbotix’s humanoid robot was featured as a live connected endpoint in Ericsson’s pre-standard 6G over-the-air trial at Ericsson’s U.S. headquarters in Plano, Texas on March 25, 2026. The robot streamed video and interacted in real time over Ericsson’s test network, demonstrating AI-agnostic integration across cloud and network environments. Onconetix reiterated its definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction announced February 12, 2026; closing and Nasdaq listing are expected in the second half of 2026, subject to shareholder and regulatory approvals.
Positive
- Realbotix robot featured in Ericsson 6G OTA trial (Mar 2026)
- Definitive share exchange agreement signed on Feb 12, 2026
- Combined company expected to trade on Nasdaq in H2 2026
Negative
- Acquisition is an all-stock transaction (shareholder dilution risk)
- Deal closing subject to shareholder and regulatory approvals
- Closing timing uncertain—anticipated in second half of 2026
News Market Reaction – ONCO
On the day this news was published, ONCO gained 5.67%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.2% during that session. Argus tracked a trough of -21.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $150K to the company's valuation, bringing the market cap to $2.79M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ONCO was down 4.69% while biotech peers like APVO (-5.56%), OGEN (-3.3%), QNRX (-0.68%), XBIO (-1.32%) and SXTP (-21.55%) mostly declined. Momentum scans only flagged SXTP moving up earlier, suggesting ONCO’s move was more stock-specific than part of a synchronized sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Reverse stock split | Negative | -3.0% | 1-for-5 reverse split to address Nasdaq minimum bid requirement. |
| Feb 12 | Acquisition announcement | Neutral | -42.7% | All-stock deal to acquire Realbotix LLC, shifting control to seller. |
| Feb 12 | Counterparty deal note | Neutral | -42.7% | Realbotix Corp. outlines sale terms granting 75–90% ONCO ownership. |
| Sep 26 | Financing & debt deal | Positive | +6.3% | Private placement and Veru debt settlement to bolster balance sheet. |
| Sep 26 | Merger termination | Neutral | +6.3% | Mutual termination of Ocuvex merger, each pursuing independent paths. |
Recent history shows sharp negative reactions to capital structure and transformational M&A news, with occasional positive moves on financing and balance-sheet actions.
Over the last six months, Onconetix has undergone significant strategic and capital changes. A 1-for-5 reverse split on Mar 23, 2026 preceded today’s Realbotix 6G-related update. The Feb 12, 2026 all-stock Realbotix acquisition news saw a 42.7% drop, indicating investor concern about dilution and control shifting, even as the combined company aimed to remain on Nasdaq. Earlier, a $12.9M private placement and Veru debt settlement on Sep 26, 2025 coincided with a 6.27% gain, showing markets sometimes rewarded de-leveraging despite dilution.
Market Pulse Summary
The stock moved +5.7% in the session following this news. A strong positive reaction aligns with how transformational technology milestones can reframe prior concerns about dilution and control. The Ericsson 6G trial involvement underscores Realbotix’s positioning in next‑generation connectivity and AI, while earlier filings highlighted substantial going‑concern risks and large ownership shifts of 75–90%. Investors would need to weigh enthusiasm for AI robotics against execution on required approvals and cash conditions like the $12.5 million Net Cash threshold.
Key Terms
over-the-air technical
ota technical
ai-agnostic technical
equity interests financial
AI-generated analysis. Not financial advice.
Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix
CINCINNATI, Ohio, March 25, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) wishes to draw its shareholders’ attention to a development reported by Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) (“Realbotix Corp.”), the parent company of Realbotix LLC, the target of Onconetix’s previously announced pending acquisition.
Realbotix Corp. announced that one of its humanoid robots, which had been purchased by Ericsson — Realbotix’s first enterprise client — was featured in Ericsson’s recently completed live pre-standard 6G over-the-air (OTA) trial conducted at Ericsson’s U.S. headquarters in Plano, Texas. Onconetix is sharing this development with its shareholders as it relates to the capabilities of Realbotix, the target of the pending acquisition.
During the demonstration, the Realbotix humanoid robot served as a live robotics endpoint, transmitting video and interacting in real time over Ericsson’s test network. Ericsson’s demonstration showcased how next-generation wireless networks can power AI robotics and real-time video streaming, highlighting the type of high-speed, low-latency connectivity expected to support future AI-driven technologies.
The demonstration also highlighted Realbotix’s AI-agnostic architecture, which enables its humanoid robots to integrate with a variety of AI systems, cloud platforms, and network environments. This flexible approach is designed to allow Realbotix robots to operate across diverse ecosystems without dependence on any single AI provider or software stack.
As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire
The full text of Realbotix Corp.’s press release regarding the Ericsson trial, including the complete forward-looking statement disclaimer applicable to Realbotix Corp., is available at www.realbotix.ai and on Realbotix Corp.’s SEDAR+ filing profile at www.sedarplus.ca.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
FAQ
What did Onconetix (ONCO) announce about Realbotix and Ericsson on March 25, 2026?
When did Onconetix sign the definitive agreement to acquire Realbotix LLC (ONCO)?
Will the combined company of Onconetix (ONCO) and Realbotix trade on Nasdaq, and when?
What did Ericsson’s 6G trial demonstration show about Realbotix’s technology?
